About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials | 6,585 Studies Recruiting

Clinical TrialsLymphoma

Lymphoma Clinical Trials

Browse 6,585 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 2381-2400 of 6,585 trials

CompletedBrazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLNational, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma…NCT05958134·Belo Horizonte and 3 others UnknownStudy of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).NCT04534634·Suzhou, Jiangsu TerminatedRituximab Maintenance After Autologous TransplantationThe goal of this clinical research is to see if Rituxan (rituximab) therapy given after high dose chemotherapy and transplant of a patients own stem cells will prevent or delay…NCT01103388·Houston, Texas CompletedS9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell LymphomaRATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.NCT01563861 TerminatedMP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or LymphomaRATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.NCT00504205·Scottsdale, Arizona and 1 other

Related Searches

hodgkintrials non-hodgkintrials

Data from ClinicalTrials.govTerms

CompletedSAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaThe primary objective is to determine the maximum tolerated dose (MTD) of SAR3419 according to the dose limiting toxicities (DLTs) observed when administered as a single agent…NCT00796731·Créteil and 5 others

Not yet recruitingStudy of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaOpen-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma.NCT07477366

WithdrawnDose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaThe main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials.NCT02215629

CompletedA Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's LymphomaPatients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab.NCT00315731

CompletedRituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell LymphomaRATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00005631·New York, New York

Active not recruitingPolatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaThis phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double, triple hit lymphoma, Double…NCT04479267·Detroit, Michigan

CompletedAn Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's LymphomaThis first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of…NCT02783300·Denver, Colorado and 14 others

CompletedTo Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCLPart 1 (Phase Ib) Primary objective: To establish the maximum tolerated dose (MTD) of BI 836826 in combination with GemOx.NCT02624492·Hasselt and 6 others

Not yet recruitingZanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone LymphomaThe goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy.NCT07299331

CompletedDose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantThis clinical trial studies personalized dose monitoring of busulfan and combination chemotherapy in treating patients with Hodgkin or non-Hodgkin lymphoma undergoing stem cell…NCT01959477·Cleveland, Ohio

Active not recruitingTreatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.First line treatment with combination rituximab and golcadomide with, or without nivolumab, in patients in previously untreated Follicular LymphomaNCT05788081·Ballarat, Victoria and 4 others

UnknownNon-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI18F-FDG PET/MR imaging protocol integrating advanced MR vascular imaging sequences, along with computerized quantitative methods for data analysis, is expected to serve as an…NCT04154228

CompletedA Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaThis is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with…NCT00636792·Washington D.C., District of Columbia and 1 other

CompletedAn Open Label Dose Escalation Study Of E7080The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.NCT00121719·Amsterdam and 1 other

UnknownRituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's LymphomaThe purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and…NCT00041730·La Jolla, California and 14 others

PreviousPage 120 of 330Next